AR113965A1 - Triazol azoles ciclohexil ácidos como antagonistas de lpa - Google Patents
Triazol azoles ciclohexil ácidos como antagonistas de lpaInfo
- Publication number
- AR113965A1 AR113965A1 ARP180103701A ARP180103701A AR113965A1 AR 113965 A1 AR113965 A1 AR 113965A1 AR P180103701 A ARP180103701 A AR P180103701A AR P180103701 A ARP180103701 A AR P180103701A AR 113965 A1 AR113965 A1 AR 113965A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nrcrc
- nrbc
- orb
- haloalkyl
- Prior art date
Links
- -1 TRIAZOLE AZOLES CYCLOHEXYL ACIDS Chemical class 0.000 title abstract 7
- 239000002253 acid Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 8
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 8
- 125000001188 haloalkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 8
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 abstract 7
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000003282 alkyl amino group Chemical group 0.000 abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000005884 carbocyclylalkyl group Chemical group 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 125000004992 haloalkylamino group Chemical group 0.000 abstract 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de la fórmula (1), o un estereoisómero, tautómero o solvato o sal de aquellos aceptable desde el punto de vista farmacéutico, en donde todas las variables son como se definen en la presente. Estos compuestos son inhibidores selectivos del receptor de LPA. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), o un estereoisómero, un tautómero, un solvato o una sal de aquellos aceptables desde el punto de vista farmacéutico, en donde X¹, X², X³ y X⁴ son, cada uno independientemente, CR⁵ o N; siempre que no más de dos de X¹, X², X³ o X⁴ sean N; uno de Q¹, Q² y Q³ es NR⁶, y los otros dos son N; y el circulo discontinuo indica enlaces opcionales que forman un anillo aromático; L es un enlace covalente o C₁₋₄ alquileno sustituido con 0 a 4 R⁷; Z es CHR⁸ᵃ, NR⁸ᵇ u O; el anillo Y es un heteroarilo de 5 miembros o heterociclilo de 5 miembros, en donde cada uno contiene independientemente un átomo de nitrógeno y al menos un heteroátomo adicional seleccionado de nitrógeno, oxígeno y azufre; R¹ es (-CH₂)ₐR⁹; a es un entero de 0 ó 1; R² es, cada uno independientemente, halo, ciano, hidroxilo, amino, C₁₋₆ alquilo, C₃₋₆ cicloalquilo, heterociclilo de 4 a 6 miembros, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxi, alcoxialquilo, haloalcoxialquilo o haloalcoxi; n es un entero de 0, 1 ó 2; R³ es halo, ciano, hidroxilo, amino, oxo, -ORᵃ, -SRᵃ, =S, -NRᶜRᶜ, =NH, =N-OH, =NRᵃ, =N-ORᵃ, -NO₂, -S(O)₂Rᵃ, -S(O)₂NHRᵇ, -S(O)₂NRᶜRᶜ, -S(O)₂ORᵇ, -OS(O)₂Rᵇ, -OS(O)₂ORᵇ, -P(O)(ORᵇ)(ORᵇ), -C(O)Rᵇ, C(NRᵇ)Rᵇ, -C(O)ORᵇ, -C(O)NRᶜRᶜ, -C(NRᵇ)NRᶜRᶜ, -OC(O)Rᵇ, -NRᵇC(O)Rᵇ, -OC(O)ORᵇ, -NRᵇC(O)ORᵇ, -OC(O)NRᶜRᶜ, -NRᵇC(O)NRᶜRᶜ, -NRᵇC(NRᵇ)Rᵇ, -NRᵇC(NRᵇ)NRᶜRᶜ, C₁₋₆ alquilo, C₁₋₆ alquilo deuterado (deuterado de manera total o parcial), C₂₋₆ alquenilo, C₁₋₆ haloalquilo, C₁₋₆ heteroalquilo, arilo de 6 a 10 miembros, arilalquilo, heteroarilo de 5 a 10 miembros, heteroarilalquilo, carbociclilo de 3 a 8 miembros sustituido con 0 a 1 =CH₂, carbociclilalquilo, heterociclilo de 4 a 8 miembros o heterociclilalquilo; en donde el alquilo, heteroalquilo, arilo, heteroarilo, carbociclilo, heterociclilo y Rᵃ, en si mismos o como parte de otro grupo, se sustituyen, cada uno independientemente, con 0 a 5 Rᵈ; Rᵃ se selecciona de C₁₋₆ alquilo, C₁₋₆ alquilo deuterado, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, carbociclilo, carbociclilalquilo, heterociclilo y heterociclilalquilo; Rᵇ es, cada uno independientemente, hidrógeno o Rᵃ; Rᶜ es, cada uno independientemente, Rᵇ; o, alternativamente, dos Rᶜ, junto con el átomo de nitrógeno al que están unidos, forman un heterociclilo de 4 a 7 miembros; Rᵈ se selecciona, cada uno independientemente, de Rᵃ, alcoxi, haloalcoxi, alquilamino, cicloalquilamino, heterociclilamino, haloalquilo, hidroxialquilo, aminoalquilo, cicloalcoxi, heterocicliloxi, haloalcoxi, alcoxialcoxi, haloalquilamino, alcoxialquilamino, haloalcoxialquilamino, arilamino, aralquilamino, ariloxi, aralquiloxi, heteroariloxi, heteroarilalquiloxi, alquiltio, halo, ciano, hidroxilo, amino, oxo, -ORᵃ, -SRᵃ, =S, -NRᶜRᶜ, =NH, =N-OH, =NRᵃ, =N-ORᵃ, -NO₂, -S(O)₂Rᵃ, -S(O)₂NHRᵇ, -S(O)₂NRᶜRᶜ, -S(O)₂ORᵇ, -OS(O)₂Rᵇ, -OS(O)₂ORᵇ, -P(O)(ORᵇ)(ORᵇ), -C(O)Rᵇ, -C(NRᵇ)Rᵇ, -C(O)ORᵇ, -C(O)NRᶜRᶜ, -C(NRᵇ)NRᶜRᶜ, -OC(O)Rᵇ, -NRᵇC(O)Rᵇ, -OC(O)ORᵇ, -NRᵇC(O)ORᵇ, -NRᵇC(O)NRᶜRᶜ, -NRᵇC(NRᵇ)Rᵇ y -NRᵇC(NRᵇ)NRᶜRᶜ; o, alternativamente, uno o dos Rᵈ en alquilo, heteroalquilo, arilo, heteroarilo, carbociclilo o heterociclilo, junto con los átomos a los que están unidos, forman una porción puente o cíclica; R⁴ es, cada uno independientemente, halo, hidroxilo, amino, ciano, -C(O)NH₂, -C(O)NR¹²ᵃR¹²ᵇ, C(O)OR¹²ᵃ, C₁₋₄ alquilo, C₁₋₄ haloalquilo, C₂₋₆ alcoxialquilo, C₁₋₄ alcoxi, oxo (=O) o imino (=NH); o, alternativamente, R³ y R⁴, junto con los átomos a los que están unidos, forman una porción carbociclilo o heterociclilo; m es un entero de 0, 1 ó 2; R⁵ es hidrógeno, halo, ciano, hidroxilo, amino, C₁₋₆ alquilo, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R⁶ es hidrógeno, C₁₋₆ alquilo, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R⁷ es halo, oxo, ciano, hidroxilo, amino, C₁₋₆ alquilo, C₃₋₆ cicloalquilo, heterociclilo de 4 a 6 miembros, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R⁸ᵃ es hidrógeno, halo, ciano o C₁₋₄ alquilo; R⁸ᵇ es hidrógeno o C₁₋₄ alquilo; R⁹ se selecciona de -CN, -C(O)OR¹⁰, -C(O)NR¹¹ᵃR¹¹ᵇ, o un resto seleccionado del grupo de fórmulas (2); Rᵉ es C₁₋₆ alquilo, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo o haloalcoxialquilo; R¹⁰ es hidrógeno o C₁₋₁₀ alquilo; R¹¹ᵃ y R¹¹ᵇ son, cada uno independientemente, hidrógeno, C₁₋₆ alquilo, C₃₋₆ cicloalquilo, heterociclilo de 4 a 6 miembros, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R¹²ᵃ es C₁₋₄ alquilo; y R¹²ᵇ es hidrógeno o C₁₋₄ alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607488P | 2017-12-19 | 2017-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113965A1 true AR113965A1 (es) | 2020-07-01 |
Family
ID=65003581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103701A AR113965A1 (es) | 2017-12-19 | 2018-12-18 | Triazol azoles ciclohexil ácidos como antagonistas de lpa |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11319315B2 (es) |
| EP (1) | EP3728224B1 (es) |
| JP (1) | JP7280881B2 (es) |
| KR (1) | KR20200100713A (es) |
| CN (1) | CN111712492B (es) |
| AR (1) | AR113965A1 (es) |
| AU (1) | AU2018392325A1 (es) |
| BR (1) | BR112020012177A2 (es) |
| CA (1) | CA3085938A1 (es) |
| EA (1) | EA202091505A1 (es) |
| ES (1) | ES2938863T3 (es) |
| IL (1) | IL275363A (es) |
| MX (1) | MX2020005818A (es) |
| SG (1) | SG11202005703TA (es) |
| TW (1) | TW201927778A (es) |
| WO (1) | WO2019126094A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI830713B (zh) | 2017-12-19 | 2024-02-01 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸 |
| ES2944304T3 (es) * | 2017-12-19 | 2023-06-20 | Bristol Myers Squibb Co | Pirazol azinas de ácido ciclohexílico como antagonistas de LPA |
| CN113260310A (zh) * | 2018-10-15 | 2021-08-13 | 百时美施贵宝公司 | 用于成像lpa1受体的放射性配体 |
| CN111434653A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| EP3986553A1 (en) | 2019-06-18 | 2022-04-27 | Bristol-Myers Squibb Company | Cyclobutyl carboxylic acids as lpa antagonists |
| KR102775995B1 (ko) | 2019-11-15 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
| CA3185689A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| EP4196220A1 (en) * | 2020-08-11 | 2023-06-21 | Viva Star Biosciences Limited | Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists |
| ES3049795T3 (en) * | 2020-10-22 | 2025-12-18 | Lhotse Bio Inc | Compounds and compositions for treating conditions associated with lpa receptor activity |
| CN114621135B (zh) * | 2020-12-11 | 2024-01-30 | 上海拓界生物医药科技有限公司 | 一种lpa1小分子拮抗剂 |
| AU2022273631B2 (en) | 2021-05-11 | 2025-04-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022241023A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| AU2022327398A1 (en) * | 2021-08-12 | 2024-03-21 | Shanghai SIMR Biotechnology Co., Ltd | Substituted triazole derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof |
| CN118541360A (zh) | 2021-12-08 | 2024-08-23 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與lpa受體活性相關的病狀的化合物及組合物 |
| CN115785014B (zh) * | 2022-12-27 | 2025-01-24 | 瑞石生物医药有限公司 | 四唑衍生物及其用途 |
| US12359594B2 (en) | 2023-08-01 | 2025-07-15 | Discovery Energy, Llc | Convertible silencer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE447970T1 (de) | 2001-02-08 | 2009-11-15 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| DE102004038403B4 (de) | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| AU2009231953A1 (en) | 2008-04-04 | 2009-10-08 | Irm Llc | Compounds and compositions as ITPKB inhibitors |
| JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス,インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| EA201390821A1 (ru) | 2010-12-07 | 2013-10-30 | Амира Фармасьютикалс, Инк. | Антагонисты рецепторов лизофосфатидной кислоты и их применение |
| US8785442B2 (en) | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| WO2012137982A2 (en) | 2011-04-05 | 2012-10-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| BR112014006924B1 (pt) | 2011-09-27 | 2020-10-06 | Genfit | Derivados de triazolopiridazinas 6-substituídas como agonistas de rev-erb |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| WO2013085824A1 (en) | 2011-12-04 | 2013-06-13 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| US9187474B2 (en) | 2012-03-07 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
| US20150133512A1 (en) | 2012-06-20 | 2015-05-14 | Hoffmann-La Roche Inc, | N-aryltriazole compounds as lpar antagonists |
| KR20150021057A (ko) | 2012-06-20 | 2015-02-27 | 에프. 호프만-라 로슈 아게 | Lpar 길항제로서의 n-알킬트라이아졸 화합물 |
| JP6853619B2 (ja) | 2015-01-16 | 2021-03-31 | 大塚製薬株式会社 | シアノトリアゾール化合物の医薬用途 |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| TWI830713B (zh) | 2017-12-19 | 2024-02-01 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸 |
-
2018
- 2018-12-18 CA CA3085938A patent/CA3085938A1/en not_active Abandoned
- 2018-12-18 ES ES18830682T patent/ES2938863T3/es active Active
- 2018-12-18 BR BR112020012177-0A patent/BR112020012177A2/pt not_active Application Discontinuation
- 2018-12-18 EP EP18830682.3A patent/EP3728224B1/en active Active
- 2018-12-18 AR ARP180103701A patent/AR113965A1/es unknown
- 2018-12-18 JP JP2020533765A patent/JP7280881B2/ja active Active
- 2018-12-18 MX MX2020005818A patent/MX2020005818A/es unknown
- 2018-12-18 CN CN201880089521.5A patent/CN111712492B/zh active Active
- 2018-12-18 AU AU2018392325A patent/AU2018392325A1/en not_active Abandoned
- 2018-12-18 WO PCT/US2018/066123 patent/WO2019126094A1/en not_active Ceased
- 2018-12-18 US US16/772,842 patent/US11319315B2/en active Active
- 2018-12-18 SG SG11202005703TA patent/SG11202005703TA/en unknown
- 2018-12-18 TW TW107145552A patent/TW201927778A/zh unknown
- 2018-12-18 KR KR1020207020532A patent/KR20200100713A/ko not_active Withdrawn
- 2018-12-18 EA EA202091505A patent/EA202091505A1/ru unknown
-
2020
- 2020-06-14 IL IL275363A patent/IL275363A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202091505A1 (ru) | 2020-09-22 |
| TW201927778A (zh) | 2019-07-16 |
| US20210163470A1 (en) | 2021-06-03 |
| CN111712492A (zh) | 2020-09-25 |
| JP7280881B2 (ja) | 2023-05-24 |
| KR20200100713A (ko) | 2020-08-26 |
| ES2938863T3 (es) | 2023-04-17 |
| SG11202005703TA (en) | 2020-07-29 |
| CN111712492B (zh) | 2024-05-31 |
| CA3085938A1 (en) | 2019-06-27 |
| BR112020012177A2 (pt) | 2020-11-24 |
| AU2018392325A1 (en) | 2020-07-30 |
| JP2021507900A (ja) | 2021-02-25 |
| WO2019126094A1 (en) | 2019-06-27 |
| IL275363A (en) | 2020-07-30 |
| EP3728224A1 (en) | 2020-10-28 |
| EP3728224B1 (en) | 2023-01-11 |
| US11319315B2 (en) | 2022-05-03 |
| MX2020005818A (es) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113965A1 (es) | Triazol azoles ciclohexil ácidos como antagonistas de lpa | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR113820A1 (es) | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR127309A2 (es) | Derivados de piridazinona | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR118435A1 (es) | Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
| AR108875A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR094704A1 (es) | Compuestos y composiciones como degradantes selectivos del receptor de estrógeno | |
| AR109964A1 (es) | Derivados de aril-sulfonamidas como bloqueadores del canal de sodio | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR118247A1 (es) | Combinación de compuestos activos | |
| AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico | |
| AR113819A1 (es) | Compuestos espirocíclicos como moduladores del receptor farnesoide x | |
| AR115936A1 (es) | Compuestos útiles en terapia del vih | |
| EA201791816A1 (ru) | Ингибиторы kv1.3 и их применение в медицине | |
| AR124718A1 (es) | Quinolinas y azaquinolinas como inhibidores de cd38 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |